Zota Health Care Ltd. stock analysis
Want to see IN:ZOTA full AI Analyst Report?
Zota Health Care Ltd. (ZOTA) Stock Price & Analysis
ZOTA Stock Chart & Stats
- Day’s Range
- INR 1,285.00 - INR 1,330.00
- 52-Week Range
- INR 1,022.00 - INR 1,740.00
- Previous Close
- INR 1,287.60
- Volume
- N/A
- Average Volume (3M)
- 63.72K
- Market Cap
- INR 39.15B
- Enterprise Value
- INR 46.79B
- Total Cash (Recent Filing)
- INR 775.50M
- Total Debt (Recent Filing)
- INR 2.71B
- Price to Earnings (P/E)
- ―
- Beta
- 0.91
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 2.3
- Last Dividend Ex-Date
- Sep 21, 2026
- Dividend Yield
- 0.08%
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
Rapidly accelerating revenue indicates expanding sales activity and stronger market reach across the company’s pharmaceutical portfolio. If Zota can retain customers and improve economics, this growing base could support operating leverage, broader distribution, and stronger earnings capacity over the next several quarters.
Meaningful Equity Base
A larger equity base provides a buffer against operating volatility and keeps reported leverage moderate despite the company’s recent debt increase. This financial cushion may preserve some ability to fund operations and pursue growth while management works to restore profitability and cash generation.
Broad Branded-Generics Portfolio
A portfolio spanning multiple therapeutic categories and branded generic products gives Zota several avenues for generating sales rather than relying on one medicine or indication. Product breadth can support distribution reach, customer diversification, and more durable growth as healthcare demand develops.
Bears Say
Severe Margin Compression
The sharp deterioration in gross and net margins shows that revenue growth is not translating into economically attractive sales. Continued pricing pressure, mix changes, or cost inflation could limit operating leverage and require a substantial improvement in product economics before earnings recover.
Persistent Cash Burn
Sustained negative operating and free cash flow weakens internal funding capacity and increases dependence on external financing or balance-sheet resources. Large cash burn also raises execution risk because the company must convert rapid sales growth into cash before its financial flexibility deteriorates further.
Rising Debt Amid Losses
Although leverage remains moderate relative to equity, the scale and speed of debt growth alongside continuing losses increase financial risk. Higher obligations can constrain capital allocation and add pressure on management to restore profitability, particularly while cash flows remain materially negative.
Zota Health Care Ltd. News
ZOTA FAQ
What was Zota Health Care Ltd.’s price range in the past 12 months?
What is Zota Health Care Ltd.’s market cap?
When is Zota Health Care Ltd.’s upcoming earnings report date?
How were Zota Health Care Ltd.’s earnings last quarter?
Is Zota Health Care Ltd. overvalued?
Does Zota Health Care Ltd. pay dividends?
What is Zota Health Care Ltd.’s EPS estimate?
How many shares outstanding does Zota Health Care Ltd. have?
What happened to Zota Health Care Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zota Health Care Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Zota Health Care Ltd.
Zota Health Care Limited is an Indian pharmaceutical firm dedicated to the development, manufacturing, and distribution of a broad spectrum of health-related products across India. Its extensive portfolio encompasses generic medications, over-the-counter (OTC) remedies, traditional Ayurvedic formulations, and nutritional supplements (nutraceuticals). The company places a particular emphasis on supplying treatments for various long-term illnesses, including but not limited to heart disease, diabetes, and thyroid conditions. By March 31, 2021, Zota had established a considerable retail network, operating 591 stores under its DAVAINDIA brand name throughout 24 states in India. The company was founded in 1995 and is currently headquartered in Surat, India.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Sujit Paul
- Employees
- 635
- Website
- www.zotahealthcare.com
- Address
- Zota House, Surat, GU, 394210, IN
Zota Health Care Ltd. (ZOTA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 10 | 0 | 2 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:CONCORDBIOConcord Biotech Ltd. | ||
| IN:DCALDishman Carbogen Amcis Ltd. | ||
| IN:PANACEABIOPanacea Biotec Limited | ||
| IN:SUPRIYASupriya Lifescience Limited | ||
| IN:ONESOURCEOneSource Specialty Pharma Limited |









